MAC TEL

Actively Recruiting // Barbara Blodi // Clinical Trials // Macular Telangiectasia // Other // Dec 01 2020

Extension Study of NT-501 Ciliary Neurotrophic Factor (CNTF) Implant for Macular Telangiectasia (Mac Tel)

  • Sponsor: Neurotech Pharmaceuticals, Inc.
  • Principal Investigator: Barbara Blodi, MD
  • Study Coordinator: Kris Dietzman

Study objective:

To evaluate long term safety and efficacy of the NT-501 implant in participants that previously enrolled in the NTMT-01 and NTMT-02 protocols.

Study design:

The study will include one visit per year over a 4-year period.

Inclusion criteria:

  • Previously enrolled in the NTMT-01 or NTMT-02 protocol and received the NT-501 implant and/or underwent a Sham procedure

Exclusion criteria:

  • None

Contact Kris Dietzman with questions, 608-263-9035

For more information about this study, visit clinicaltrials.gov.